Checkpoint Therapeutics(CKPT) - 2023 Q3 - Quarterly Report

Table of Contents FORM 10-Q For the transition period from _________ to _________ Commission File Number 001-38128 Class of Common Stock Outstanding Shares as of November 10, 2023 Class A Common Stock, $0.0001 par value 700,000 Common Stock, $0.0001 par value 22,826,035 Table of Contents Risks Related to Reliance on Third Parties ● We rely, and will rely in the future, on third-party contract research organizations and contract manufacturers for the conduct of our preclinical and clinical studies and trials ...